NCT00904397终止4 期
A Randomized, Open-Label Study Comparing the Efficacy and Safety of Lidocaine Patch 5% With Celecoxib 200 mg in Patients With Chronic Axial Low Back Pain
Endo Pharmaceuticals0 个研究点目标入组 98 人开始时间: 2004年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 98
- 主要终点
- Mean change from baseline to Week 12 in BPI average pain intensity score (Question 5).
研究概览
简要总结
Patients who had axial lower back pain (LBP) with or without radiation present for at least 3 months and had daily moderate to severe LBP as the primary source of pain participated in a Phase IV clinical trial to assess the efficacy of lidocaine patch 5% compared to celecoxib 200 mg in treating chronic axial LBP with and without radiation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Had axial LBP with or without radiation present for at least 3 months as defined below:
- •Chronic axial LBP without radiation: pain isolated to the axial low back without radiation into the buttock or below
- •Chronic axial LBP with radiation: pain that radiated to the buttock or below. This patient group could include patients with radicular/neuropathic and non-radicular components with leg pain component <50%
- •Had daily moderate to severe LBP as the primary source of pain
- •Had a normal neurological examination, including:
- •Motor strength
- •Sensory exam in lower extremities
- •Deep tendon reflexes
- •Had a normal 12-lead electrocardiogram (ECG) without any clinically significant abnormalities in heart rate, rhythm, or conduction
- •Had discontinued use of all analgesic medications (including over-the-counter [OTC] analgesics), glucosamine, and chondroitin prior to randomization (patients were allowed limited use of analgesic medications for indications other than non-study pain
- •At the baseline visit, patients were randomized to active treatment if they had an average daily pain intensity score of 5 or greater (on a 0 to 10 scale) for at least 3 days out of the 5 consecutive days immediately prior to the baseline visit; 0 was defined as "no pain" and 10 was defined as "pain as bad as ever imagined" as measured by Question 5 of the Brief Pain Inventory (BPI) and recorded in a diary
排除标准
- •Had spinal stenosis with >50% leg pain component
- •Had any other chronic pain condition that, in the opinion of the investigator, would interfere with patient assessment of LBP relief
- •Had a history of one or more back surgeries within 1 year of study entry
- •Had a moderate or greater hepatic impairment
- •Had a severe renal insufficiency (creatinine clearance of <30 mL/min)
- •Had experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)
- •Had a prior history of peptic ulcer disease and/or gastrointestinal (GI) bleeding
- •Were taking analgesic medications that could not be discontinued during the study. Patients taking these medications prior to the study were required to discontinue use for the duration of the study. Patients using opioid analgesics at study entry were required to taper off these medications.
- •Were taking long-acting opioids or opioids that could not be discontinued over the first 5 days of the washout period
- •Were receiving fluconazole or lithium (secondary to drug-drug-interaction risks with celecoxib)
- •Had received an epidural steroid/local anesthetic injection within 4 weeks prior to study entry
- •Had received trigger point injections within 2 weeks prior to study entry
- •Had received Botulinum Toxin (Botox) injections for LBP within 6 months prior to study entry
- •Were using a lidocaine-containing product that cannot be discontinued during the study
- •Were using any topical medication applied to the low back region
- •Had previously failed treatment with Lidoderm analgesic patch for LBP
- •Had previously failed treatment with celecoxib or with any two COX-2 specific inhibitors other than celecoxib
- •Were taking class I anti-arrhythmic (e.g. mexiletine, tocainide)
- •Had a history of alcohol or substance abuse within the last 3 years
研究组 & 干预措施
Lidoderm
Experimental
Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 2 patches applied once daily (q24h) directly to the most painful area of the low back
干预措施: Lidoderm® (Drug)
Celecoxib
Active Comparator
Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
干预措施: Celecoxib (Drug)
结局指标
主要结局
Mean change from baseline to Week 12 in BPI average pain intensity score (Question 5).
时间窗: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)
次要结局
- Mean change from baseline to Weeks 2, 4, 6, 8, and 12 in daily pain intensity score as measured by Questions 3, 4, 5, and 6 of the BPI(Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84))
- Mean change from baseline to Weeks 2, 4, 6, 8, and 12 in BPI pain relief score (Question 8).(Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84))
- Mean change from baseline to Weeks 2, 4, 6, 8, and 12 in PQAS composite scores(Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84))
- Mean change from baseline to Weeks 2, 4, 6, 8, and 12 in Oswestry Disability Index composite scores(Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84))
- Investigator's Global Impression of Change in LBP at Week 12 (or premature discontinuation)(Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84))
- Patient's Global Impression of Change in LBP at Week 12 (or premature discontinuation)(Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84))
- Investigator's Global Assessment of Treatment Satisfaction at Week 12 (or premature discontinuation)(Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84))
- Patient's Global Assessment of Treatment Satisfaction at Week 12 (or premature discontinuation)(Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84))
- Safety assessments included AEs (including discontinuation due to AEs).(Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84))
- Safety assessments included dermal assessment (lidocaine group only), skin sensory testing (lidocaine group only), clinical laboratory test results (including urinalysis, vital signs measurements, physical and neurological examinations, and body weight.(Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84))
- Safety assessments included plasma lidocaine concentrations (lidocaine group only).(Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84))
研究者
相似试验
已完成
4 期
Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back PainChronic Low Back PainNCT00904475Endo Pharmaceuticals102
已完成
4 期
Topical Lidocaine Patch in Low Back PainAcute and Chronic Non-radicular LBPNCT00904540Endo Pharmaceuticals131
已完成
2 期
PF-06372865 In Subjects With Chronic Low Back PainChronic Low Back PainNCT02262754Pfizer302
已完成
早期 1 期
Intraarticular Lumbar Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected PopulationLow Back PainNCT01382771University of Florida28
已完成
不适用
Pain Relief in Patients With Chronic Low Back Pain Using HeatTens vs. Standard Care.Chronic Low Back PainMovement Evoked PainNCT03643731Vrije Universiteit Brussel50